[Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma].

MLA

Zhou, B. J., et al. “[Preliminary Clinical Use of Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Tislelizumab in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma].” Zhonghua Nei Ke Za Zhi, vol. 63, no. 8, Aug. 2024, pp. 769–75. EBSCOhost, https://doi.org/10.3760/cma.j.cn112138-20231102-00287.

APA

Zhou, B. J., Wang, W. S., Yin, Y., Yang, J., Zhu, X. L., & Ni, C. F. (2024). [Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma]. Zhonghua Nei Ke Za Zhi, 63(8), 769–775. https://doi.org/10.3760/cma.j.cn112138-20231102-00287

Chicago

Zhou, B J, W S Wang, Y Yin, J Yang, X L Zhu, and C F Ni. 2024. “[Preliminary Clinical Use of Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Tislelizumab in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma].” Zhonghua Nei Ke Za Zhi 63 (8): 769–75. doi:10.3760/cma.j.cn112138-20231102-00287.